Related Experiment Videos
Pharmacological reevaluation of gitoxin in man
International Journal of Clinical Pharmacology and Biopharmacy
|October 1, 1978
Summary
Gitoxin, a cardiac glycoside, is well-absorbed orally and impacts left ventricular ejection time index similarly to digoxin. Its short half-life and reduced renal dependence offer advantages in patient care.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Pharmacokinetics
Background:
- Cardiac glycosides like digoxin and digitoxin are crucial in managing heart failure.
- Understanding the pharmacokinetic and pharmacodynamic profiles of related compounds is essential for optimizing therapeutic use.
- Gitoxin, a related cardiac glycoside, requires reevaluation of its clinical parameters.
Purpose of the Study:
- To reevaluate the pharmacokinetic and pharmacodynamic parameters of gitoxin in human subjects.
- To compare gitoxin's effects and elimination with digoxin and digitoxin.
- To identify potential advantages of gitoxin in clinical settings.
Main Methods:
- Oral administration of gitoxin solution to fasting subjects.
- Measurement of plasma concentrations and urinary excretion.
- Assessment of the left ventricular ejection time index (LVETI).
Main Results:
- Gitoxin demonstrates quasi-complete absorption after oral administration.
- A 1.5 mg dose of gitoxin modifies LVETI, comparable to digoxin and digitoxin.
- The biological half-life of gitoxin is approximately one day.
- Urinary elimination of gitoxin is less than 21% of the administered dose.
Conclusions:
- Gitoxin exhibits a short biological half-life, facilitating easier dose management.
- Gitoxin's elimination is less reliant on renal function, making it suitable for patients with impaired kidney function.
- These characteristics present significant advantages of gitoxin over digoxin and digitoxin in clinical practice.